Gossamer Bio Finalizes Distressed Debt Exchange, Converting $181M in Notes
Summary
Gossamer Bio announced the final results of its distressed debt exchange, successfully converting $181.05 million of its 5.00% Convertible Senior Notes due 2027 into new debt and highly dilutive equity.
Key Events
-
Final Tender Results Announced
Gossamer Bio announced the final results of its exchange offer for its 5.00% Convertible Senior Notes due 2027, following previous updates on the distressed debt exchange.
-
Significant Debt Converted
$181.05 million in aggregate principal amount of existing convertible notes were successfully exchanged, providing a crucial reduction in immediate debt burden.
-
Remaining Debt Outstanding
$18.95 million of the original 5.00% Convertible Senior Notes due 2027 will remain outstanding after the exchange offer.
-
New Securities Issued
The exchange involved issuing new 7.50% Convertible Senior Secured First Lien Notes due 2030 (up to $72.0M), up to 317,647,058 shares of common stock (or prefunded warrants), and purchase warrants, indicating substantial dilution.
Analysis
This filing confirms the successful completion of the distressed debt exchange, a critical step for Gossamer Bio which has been facing severe financial distress, a going concern warning, and a Nasdaq delisting notice. While the exchange involves significant dilution through the issuance of new equity and warrants, it substantially reduces the company's immediate debt burden by converting $181.05 million of existing convertible notes. This provides a crucial lifeline and extends the company's financial runway, albeit at a high cost to existing shareholders. The remaining $18.95 million in notes will stay outstanding.
At the time of this filing, GOSS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82M. The 52-week trading range was $0.14 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.